2019 Early Confirmed Speakers

 

 

  • Jeff Myers , CEO, Medicaid Health Plans of America

  • Luc Boileau , Président-directeur general, INESSS

  • Carla Deakin , Associate Director – Accelerated Access Collaborative Secretariat & NICE Office for Market Access, NICE

  • Bart Vermeulen , Deputy Director Healthcare at Office of the Minister of Social Affairs and Public Health, Belgian Federal Government 

  • Charles-Etienne de Cidrac , Director Health, AXA

  • Wim Goettsch , Special HTA-advisor, Dutch National Health Care Institute (Zorginstituut Nederland)

  • Giuseppe Rosano , Member of the Cardiovascular Working Party, EMA

  • Malcolm Qualie , Pharmacy Lead, Specialised Commissioning, NHS England

  • Sheela Upadhyaya , Associate Director Highly Specialised Technologies, Centre for Health Technology Evaluation, NICE

  • Carlos Sanchez Pavón , EMEA Regional Director, Promexico

  • Detlev Parow , Head of Department of Medicines, Therapeutic Appliances and Remedies, DAK-Gesundheit

  • Diar Fattah , Associate Director of Medicines Optimisation, NHS Dartford, Gravesham and Swanley CCG

  • Tanya Potashnik , Director, Policy and Economics Analysis Branch, Analysis Branch, Patented Medicine Prices Review Board, Government of Canada

  • Nneka Onwudiwe , PRO/PE Scientific Reviewer, FDA

  • Edmund Pezalla , Former VP Pharmaceutical Policy and Strategy, Aetna

  • Antje Behring , Team Leader and Senior Scientific Advisor, G-BA

  • Steinar Madsen , Medical Director, Norwegian Medicines Agency

  • Martin Van Der Graaff , Secretary Scientific Advisory Board (WAR), National Health Care Institute (Zorginstituut Nederland)

  • Rob Scott , Chief Medical Officer and VP Development, AbbVie

  • Isabel Torres , Vice President Market Access, Public Affairs and Patient Advocacy for Europe and Canada, Takeda

  • Navin Joshi , Head of Pricing & Access Capabilities, Emerging Markets & Asia Pacific, GSK

  • Ben Gannon , Senior Director of Global Government Affairs and Policy, Vertex Pharmaceuticals

  • Ana Plata , Global Head, Access Strategy for New Medicines, UCB

  • Andrew Richards , Senior Director, Head of Global Market Access & Pricing, Ferring International 

  • David Pritchard , VP & Area Head Africa and Developing Countries, GSK

  • Igor Rudychev , Sr. Director, Business Insights, Immuno-Oncology, AstraZeneca 

  • Adam Plich , Vice President, Head of Pricing & Market Access Europe, Teva Pharmaceuticals

  • Dan Pettitt , Global Head, Immunology Market Access (Health Economics and Reimbursement) & Policy, Johnson & Johnson

  • Mig Sleeper , VP, Head of Global Market Access & Pricing, Astellas Pharmaceuticals

  • Simon Shohet , Senior Director, Global Market Access and Pricing, Ipsen

  • Steven Flostrand , Senior Director, Pricing & Market Access, Celgene

  • Darren Walsh , Senior Director - Market Access & Govt. Affairs – EU, Orchard Therapeutics

  • Farzana Malik , Vice President Market Access, Vicarius Pharmaceuticals

  • Marco Rauland , Global Head Pricing & Payer Excellence, Merck

  • Francis Pang , VP and Head, Global Market Access, Amicus Theraputics

  • Siva Narayanan , Vice President and Global Head, Market Access, PTC Therapeutics

  • Chris Hill , Head of Strategic Pricing UK & Ireland, Sanofi

  • Paul Robinson , Executive Director, Scientific Medical & Patient Perspective, MSD

  • Keiko Tone , VP, Global Market Access, Shionogi Limited

  • Victor Lino Mendonça , Head of Policy & Market Access – Europe, Mylan

  • Erik Smets , Vice President, Head of Patient Experience and Value, UCB

  • Reg Waldeck , Market Access Strategy Leader, Bayer

  • Gundula Schneidewind , Managing Director, Takeda Belgium

  • Diego Ardigò , R&D Rare Diseases Unit Head, Chiesi Group

  • Melvin Olson , Global Head of HEOR, Novartis

  • Sue Naeyaert , Global Head Government Affairs and Policy Biosimilars, Fresenius Kabi

  • Sachin Kamal-Bahl , Vice President & Head, Global Health & Value Innovation Center, Pfizer

  • Clive Whitcher , Vice President of Global Pricing and Patient Access, Sobi

  • Paul Newton , Director Strategic Pricing & Market Access EMEA Canada, UCB

  • Nicola Redfern , Director, Access Value and Evidence Strategy UK, bluebird bio 

  • Anastasiya Stepanova , Government Affairs Manager, STADA

  • Sophie Beucher , Global Value & Access Lead, Sanofi 

  • Marco Penske , Head Market Access & Healthcare Affairs, Boehringer Ingelheim

  • William Dunlop , Head of Market Access, Mundi pharma International

  • Adam Heathfield , Senior Director, Global Health and Value Innovation Centre, Pfizer

  • Etienne Jousseaume , Head Market Access, Cell & Gene Therapies Europe, Novartis

  • Natalya Danchenko , Global Market Access and Pricing Director, Ipsen

  • Michael Schroter , Head of Personalised Reimbursment Models, Global Pricing and Market Access, Roche

  • Diann Potestio , Senior Director, National Accounts, Multiple Sclerosis & Immunology, Sanofi Genzyme

  • John Alter , VP Global Health & Value, Global Established Pharma Business Unit, Pfizer

  • Martin Whitehead , Associate Director of Market Access UK and Ireland, Jazz Pharmaceuticals

  • Adrian Griffin , VP, HTA Policy, Johnson & Johnson

  • Jenny Hughes , Head, Market Access Capabilities, GSK

  • Daria Tolkacheva , Head of Health Economics, BIOCAD

  • Fabrizio Zucca , Director Patient Access Central Europe, SOBI

  • Cristina Martin-Rinconada , Associate Director Strategic Pricing, Biosimilars, Biogen

  • Omar Dabbous , Vice President of Global HEOR and RWE, Avexis

  • Sébastien Le Roux , VP, Global Market Access & Healthcare Solutions, GSK

  • Michael Lees , Head of Value, Evidence & Portfolio Strategy (EUCAN), Takeda

  • Axel Boehnke , Director Market Access & Reimbursement D-A-CH, Morphosys

  • Nadeem Ashraf , Medical Advisor – Diabetes, Lilly

  • David Boothe , Regional Commercial Head, Spark Therapeutics

  • Deven Chauhan , Senior Director, Value Evidence Leader, Immuno-inflammation, Value Evidence & Outcomes (VEO), GSK

  • Mike Crosher , Value and Access Director, Chugai Pharma

  • Karen Hockey , Director, Global Market Access & Government Affairs, Norgine

  • Gordon Lundie , Director of Market Access, Gilead Sciences 

  • Davide Finocchiaro , Global Pricing & Market Access Specialist, Chiesi

  • Dimitrios Tsourougiannis , Associate Director, EMEA Health Economics & Outcomes Research, Astellas Pharma Europe

  • Jolanda Koenders , Head of Pricing and Market Access, Novartis

  • Dawn Ireland , President, CDH international

  • Gerard Slevin , National Hospitals Manager, STADA

  • Richard Stephens , Consumer Lead, Chair Consumer Forum, National Cancer Research Institute

  • Friedhelm Leverkus , Director Health Technology Assessment & Outcomes Research, Health & Value, Pfizer

  • David Williams , Global Engagement Lead Real World Data- General Medicine and Emerging markets and Consumer Health, Sanofi

  • Enkeleida Nikai , Director, Real World Evidence, Global Patient Outcomes and Real World Evidence (GPORWE) International, Eli Lilly

  • Elena Panitti , Global RWE Capability Building Lead, Novartis

  • Marcela Junqueira , Head of Value Demonstration and Access, Shire Farmacêutica Brasil Ltda

  • Alan Hochberg , Scientific Enablement Leader, Roche 

  • James Kavanagh , HEOR and Strategic Pricing Manager, Abbvie

  • Matteo Ferrario , Value Strategy Manager, Roche

  • Jenny Ebert , Regional Account Director, Sanofi Genzyme  

  • Jose Diaz , Group Director - Intercontinental Region & Japan-Korea-Taiwan Cluster WWHEOR Markets, Bristol Myers Squibb

  • José Luis Sánchez Chorro , Head of Market Access, Shire  

  • Jorg Mahlich , Director Health Economics, Janssen Pharmaceutical K.K

  • Andrea Mantovani , Value and Access Director, Amgen 

  • Mohamed Hamada , Country Portfolio Lead, Women’s Health – Egypt & Sudan, Pfizer

  • Thomas Abbott , Global Head, Real World Informatics Capabilities and Alliances, Astellas

  • Hassan Bruneo , Associate Director, Alnylam

  • Laura Cockram , Head of Policy and Campaigns, Parkinson's UK

  • Derick Mitchell , Chief Executive, IPPOSI

  • Maarten Van Baelen , Market Access Director, Medicines for Europe 

  • Robert Orzechowski , Chief Operating Officer, Lancaster Cancer Center

  • David Watson , Director Pricing and Reimbursement, ABPI

  • Anna Bucsics , Project Advisor, MoCA

  • Francis Crawley , Executive Director, Good Clinical Practice Alliance – Europe (GCPA)

  • Alexander Natz , Secretary General, European Confederation of Pharmaceutical Entrepreneurs

  • Shameer Khader , Program Director (Healthcare Data Science and Bioinformatics), Northwell Health

  • Anne Marciniak , Affiliate, Brunel University, London 

 

 

APPLY TO SPEAK

 


“Excellent speakers and really good chance to network.”

Director Worldwide HEOR, BMS
 

 

 

<